PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16088978-0	2005	AKT activation predicts outcome in breast cancer patients treated with tamoxifen.	Tamoxifen	71-80	AKT serine/threonine kinase 1	Homo sapiens	0-3	
16088978-3	2005	The present study was carried out to test the hypothesis that AKT activation mediates tamoxifen resistance in clinical breast cancer.	Tamoxifen	86-95	AKT serine/threonine kinase 1	Homo sapiens	62-65	
16088978-9	2005	The data presented here show that the PI3K/AKT/mTOR pathway is associated with relapse and death in ERalpha-positive breast cancer patients treated with tamoxifen, supporting in vitro evidence that AKT mediates tamoxifen resistance.	Tamoxifen	153-162	AKT serine/threonine kinase 1	Homo sapiens	43-46	
16088978-9	2005	The data presented here show that the PI3K/AKT/mTOR pathway is associated with relapse and death in ERalpha-positive breast cancer patients treated with tamoxifen, supporting in vitro evidence that AKT mediates tamoxifen resistance.	Tamoxifen	153-162	AKT serine/threonine kinase 1	Homo sapiens	198-201	
16088978-9	2005	The data presented here show that the PI3K/AKT/mTOR pathway is associated with relapse and death in ERalpha-positive breast cancer patients treated with tamoxifen, supporting in vitro evidence that AKT mediates tamoxifen resistance.	Tamoxifen	211-220	AKT serine/threonine kinase 1	Homo sapiens	43-46	
16088978-9	2005	The data presented here show that the PI3K/AKT/mTOR pathway is associated with relapse and death in ERalpha-positive breast cancer patients treated with tamoxifen, supporting in vitro evidence that AKT mediates tamoxifen resistance.	Tamoxifen	211-220	AKT serine/threonine kinase 1	Homo sapiens	198-201